eng Science and Education Publishing American Journal of Educational Research 2327-6150 2021-03-25 9 3 117 124 10.12691/education-9-3-5 EDUCATION2021935 article Nso Nso mcviali@yahoo.co.uk 1 Mahmoud Nassar 1 Gilbert Ojong 2 Akwe Nyabera 2 Sofia Lakhdar 2 Mohsen Alshamam 2 Somtochukwu Nwokoye 3 Matthew Li 3 Mostafa Alfishawy 4 Debra J. Brennessel 4 Internal Medicine, Icahn School of Medicine, Mount Sinai/NYC Health Hospital, Queens, New York. Department of Internal Medicine, La Magna Health/United Regional Hospital Augusta University-University of Georgia Medical Partnership, St. Mary's Hospital 3Augusta University-University of Georgia Medical Partnership, St. Mary's Hospital Background: Coronavirus Disease 2019 (COVID-19) potentially deteriorates the immune system and triggers prothrombotic states in many patient scenarios. Clinical studies so far do not stratify the risk of thromboembolism in COVID-19 cases. Objective: This systematic review investigates the risks of thromboembolism and outcomes of anticoagulation therapy in COVID-19 patients. Methods: We searched PubMed, Cochrane Library, Embase, Web of Science, and Google Scholar to identify relevant studies assessing thromboembolism and anticoagulant therapy in COVID-19 patients. Study Selection, Data Extraction, and Synthesis: Two reviewers screened the titles and abstracts of the included studies in the context of COVID-19, thrombosis, and anticoagulant therapy. The reviewers also ascertained the elimination of duplicate articles. Results: We included eight studies based on the thromboembolism predisposition of COVID-19 (adult/elderly) patients with the status/history of cardiovascular disease, diabetes, hypertension, obesity, and hospital admission. Conclusion: Prospective studies need to explore the risks of thromboembolism in patients with COVID-19. The current body of evidence does not substantiate antithrombotic treatment for managing thromboembolism in the setting of COVID-19. The physicians must take preventive measures for reducing the incidence rate of thromboembolism in COVID-19 scenarios until the availability of definitive treatment. http://pubs.sciepub.com/education/9/3/5/education-9-3-5.pdf thromboses COVID-19 anticoagulants incidence SARS-CoV-2